Skip to main content
. 2020 Dec 1;11(48):4504–4520. doi: 10.18632/oncotarget.27830

Figure 2. Effect of different dosage regimens of HIF-1α and HIF-2α ASO on hepatic expression of inflammatory markers.

Figure 2

Mice were intraperitoneally injected with 10, 20 or 100 mg/kg HIF-1α or HIF-2α ASO, or 20 mg/kg scrambled ASO, twice per week for 2 weeks. Hepatic mRNA expression of the inflammatory markers TNFα, TGF-β, VCAM-1, CCR2, CCL2 and CXCL2 following treatment period is shown. The upper and lower dashed lines represent mean ± SD of the log2-transformed 20 mg/kg scrambled ASO data. Log2-transformed mean ± SD of other data, relative to the log2-transformed mean of the 20 mg/kg scrambled ASO treatment group, are represented as bars (n = 4 per treatment group). * p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001.